company background image
6575

SyneuRx International (Taiwan) TPEX:6575 Stock Report

Last Price

NT$70.20

Market Cap

NT$8.5b

7D

3.2%

1Y

71.8%

Updated

19 May, 2022

Data

Company Financials
6575 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

6575 Stock Overview

SyneuRx International (Taiwan) Corp., a clinical-stage biotech company, develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan.

SyneuRx International (Taiwan) Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for SyneuRx International (Taiwan)
Historical stock prices
Current Share PriceNT$70.20
52 Week HighNT$90.00
52 Week LowNT$39.70
Beta0.82
1 Month Change-10.00%
3 Month Change19.79%
1 Year Change71.85%
3 Year Change58.64%
5 Year Change-11.94%
Change since IPO-73.10%

Recent News & Updates

Mar 10
SyneuRx International (Taiwan) (GTSM:6575) Is In A Good Position To Deliver On Growth Plans

SyneuRx International (Taiwan) (GTSM:6575) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

6575TW PharmaceuticalsTW Market
7D3.2%1.5%2.0%
1Y71.8%2.9%1.7%

Return vs Industry: 6575 exceeded the TW Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: 6575 exceeded the TW Market which returned 1.7% over the past year.

Price Volatility

Is 6575's price volatile compared to industry and market?
6575 volatility
6575 Average Weekly Movement8.6%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6575 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 6575's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
2013n/aGuochuan Emil Tsaihttps://www.syneurx.com

SyneuRx International (Taiwan) Corp., a clinical-stage biotech company, develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan. Its pipeline includes Pentarlandir, which is in Phase II clinical trials for COVID-19; Airnecflu that is in Phase I clinical trials for COVID-19; NaBen, which is in Phase III clinical trials for adult schizophrenia, as well as in Phase II clinical trials adolescent schizophrenia; ClozaBen that is in Phase II clinical trials for refractory schizophrenia; NaBen, which is in Phase II clinical trials for early dementia; Tannquilynne that is in Phase II clinical trials for dementia and psychosis; Synapsinae, which is in Phase II clinical trials for early dementia and psychosis; and Synxyrin that is in Phase II clinical trials for early TRD and suicidality. SyneuRx International (Taiwan) Corp. was founded in 2013 and is based in New Taipei City, Taiwan.

SyneuRx International (Taiwan) Fundamentals Summary

How do SyneuRx International (Taiwan)'s earnings and revenue compare to its market cap?
6575 fundamental statistics
Market CapNT$8.49b
Earnings (TTM)-NT$314.93m
Revenue (TTM)n/a

0.0x

P/S Ratio

-26.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6575 income statement (TTM)
RevenueNT$0
Cost of RevenueNT$0
Gross ProfitNT$0
Other ExpensesNT$314.93m
Earnings-NT$314.93m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.61
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 6575 perform over the long term?

See historical performance and comparison

Valuation

Is SyneuRx International (Taiwan) undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


19.79x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6575's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6575's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 6575 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6575 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6575's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6575 is overvalued based on its PB Ratio (19.8x) compared to the TW Pharmaceuticals industry average (2x).


Future Growth

How is SyneuRx International (Taiwan) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


51.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SyneuRx International (Taiwan) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has SyneuRx International (Taiwan) performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-2.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6575 is currently unprofitable.

Growing Profit Margin: 6575 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6575 is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.

Accelerating Growth: Unable to compare 6575's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6575 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).


Return on Equity

High ROE: 6575 has a negative Return on Equity (-73.46%), as it is currently unprofitable.


Financial Health

How is SyneuRx International (Taiwan)'s financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6575's short term assets (NT$448.1M) exceed its short term liabilities (NT$38.3M).

Long Term Liabilities: 6575's short term assets (NT$448.1M) exceed its long term liabilities (NT$24.2M).


Debt to Equity History and Analysis

Debt Level: 6575 is debt free.

Reducing Debt: 6575 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6575 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 6575 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.3% each year


Dividend

What is SyneuRx International (Taiwan) current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6575's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6575's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6575's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6575's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6575 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Guochuan Emil Tsai

no data

Tenure

Mr. Guochuan Emil Tsai, MD PhD MAS serves as Chairman and Chief Executive Officer of SyneuRx International (Taiwan) Corp. Guochuan Emil Tsai is an Assistant Professor at Harvard Medical School. Guochuan Em...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.


Top Shareholders

Company Information

SyneuRx International (Taiwan) Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: SyneuRx International (Taiwan) Corp.
  • Ticker: 6575
  • Exchange: TPEX
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$8.486b
  • Shares outstanding: 120.88m
  • Website: https://www.syneurx.com

Location

  • SyneuRx International (Taiwan) Corp.
  • No. 99, Xintai 5th Road
  • 20th Floor-10
  • New Taipei City
  • 22175
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.